CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.83
4.93%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 3.65
Open 3.6
1-Year Change 50%
Day's Range 3.6 - 3.87
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 22, 2024 3.65 0.03 0.83% 3.62 3.68 3.41
Jul 19, 2024 3.60 0.02 0.56% 3.58 3.70 3.48
Jul 18, 2024 3.61 0.21 6.18% 3.40 3.63 3.40
Jul 17, 2024 3.49 0.14 4.18% 3.35 3.59 3.24
Jul 16, 2024 3.47 0.22 6.77% 3.25 3.47 3.21
Jul 15, 2024 3.21 0.03 0.94% 3.18 3.29 3.06
Jul 12, 2024 3.16 0.13 4.29% 3.03 3.19 2.98
Jul 11, 2024 2.96 0.16 5.71% 2.80 3.03 2.80
Jul 10, 2024 2.76 0.11 4.15% 2.65 2.77 2.60
Jul 9, 2024 2.63 0.10 3.95% 2.53 2.65 2.47
Jul 8, 2024 2.55 0.06 2.41% 2.49 2.70 2.48
Jul 5, 2024 2.49 -0.01 -0.40% 2.50 2.55 2.44
Jul 3, 2024 2.54 0.17 7.17% 2.37 2.58 2.37
Jul 2, 2024 2.43 -0.03 -1.22% 2.46 2.48 2.31
Jul 1, 2024 2.44 0.15 6.55% 2.29 2.46 2.22
Jun 28, 2024 2.26 0.00 0.00% 2.26 2.38 2.15
Jun 27, 2024 2.23 0.02 0.90% 2.21 2.53 2.21
Jun 26, 2024 2.23 0.12 5.69% 2.11 2.26 2.09
Jun 25, 2024 2.18 0.09 4.31% 2.09 2.34 2.01
Jun 24, 2024 2.20 0.77 53.85% 1.43 2.33 1.43

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

G1 Therapeutics Company profile

About G1 Therapeutics Inc

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The Company's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, G1 Therapeutics Inc revenues decreased 30% to $31.5M. Net loss increased 49% to $148.4M. Revenues reflect License revenue decrease of 55% to $20.4M. Higher net loss reflects General and Administrative - Balancing increase of 40% to $77.6M (expense), Stock-based Compensation in SGA increase of 45% to $17.3M (expense), Research & Development - Balancing value increase of 8% to $70.6M (expense).

Industry: Bio Therapeutic Drugs

700 Park Offices Drive
Suite 200
RESEARCH TRIANGLE PARK
NORTH CAROLINA 27709
US

People also watch

ETH/USD

3,463.13 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,408.86 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 21:00 (UTC)
Spread 0.60

BTC/USD

65,929.05 Price
-3.370% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

19,628.20 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading